Ascentage Pharma Group International - SIC # 8000 -

Ticker Exchange SIC # Website Latest Ticker
AAPG Nasdaq 8000 www.ascentage.cn

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascentage Pharma Group International

Exploring High Growth Tech Stocks In Asia - Jun 22nd, 2025 10:38 pm
Asian Growth Companies With Up To 33% Insider Ownership - Jun 22nd, 2025 10:35 pm
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - Jun 15th, 2025 5:30 pm
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - Jun 9th, 2025 5:30 pm
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - Jun 2nd, 2025 5:30 pm
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - Jun 2nd, 2025 5:30 pm
Asian Growth Companies With High Insider Ownership In May 2025 - May 25th, 2025 4:37 pm
High Growth Tech Stocks in Asia for May 2025 - May 25th, 2025 4:35 pm
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 - May 22nd, 2025 6:15 pm
Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? - May 11th, 2025 3:20 pm
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - Apr 28th, 2025 5:00 am
High Growth Tech Stocks in Asia to Watch This April 2025 - Apr 24th, 2025 10:38 pm
Asian Growth Companies With High Insider Ownership - Apr 24th, 2025 10:35 pm
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - Apr 23rd, 2025 5:00 pm
Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines - Apr 21st, 2025 4:10 pm
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines - Apr 21st, 2025 5:00 am
Stocks To Watch In Gloomy Market — Including This Breakout IPO - Apr 2nd, 2025 11:07 am
Asian Growth Stocks With Strong Insider Confidence - Mar 27th, 2025 4:07 pm
Exploring XD And Two Other High Growth Tech Stocks In Asia - Mar 27th, 2025 4:05 pm
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates - Mar 27th, 2025 5:00 am